Pyramid Analytics expands AI-driven Decision Intelligence with new OpenAI integration
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, announced today at the Gartner Data & Analytics Summit in Orlando, Florida, that the Pyramid 2023 release extends its already category-leading, AI-driven augmented capabilities with the integration of GPT (generative pre-trained transformer) AI technology from OpenAI—the company behind ChatGPT and DALL-E 2—throughout the platform, interoperating with its deep set of current AI technologies.
The release harnesses the new GPT AI engines to drive complex logic, data science, and machine learning code generation; AI-driven storytelling capabilities; and even AI-assisted design templates and colors. The effort extends Pyramid’s broader vision to enable and drive adoption across the enterprise by empowering all users to solve data-centric business problems through no-code and AI-assisted analytics and decision intelligence.
Key facts about Pyramid’s OpenAI integration
OpenAI is integrated throughout the Decision Intelligence Platform—including the data preparation, data science, the business analytics and spreadsheet modules, and the storyboard and publication designer modules.
- In data preparation: OpenAI can be used to generate SQL, DAX, and MDX code automatically for complex data extraction queries.
- In data science: OpenAI can be used to generate Python and R code automatically to drive machine learning logic.
- In spreadsheets: OpenAI can be used to build spreadsheet formulas for users constructing business models.
- In storyboarding and publications: OpenAI can be used to generate designs for content and graphics.
Separately, OpenAI can be used with existing natural language querying (NLQ) engines to drive and enhance broader insights on enterprise-specific data, ultimately improving the existing tools for delivering automated storytelling and textual analysis.
Market recognition
Pyramid has long been recognized as an innovator in the decision intelligence and analytics space. The company’s Decision Intelligence Platform was ranked #1 —by leading analyst firm Gartner—for “Augmented Analytics” in the 2022 Gartner Analytics and Business Intelligence (ABI) Critical Capabilities report.
Other leading analysts—such as 451 Research , Ventana Research , Dresner Advisory Services , and BARC —recognize Pyramid for its platform-based approach to no-code capabilities and AI/augmented analytics to enable all user types to drive sophisticated analytics easily. Critically, Pyramid’s existing augmented capabilities (NLQ, Chatbot, Smart Insights, Smart Model, Auto Discovery, Fill in the Blanks, Explain, etc.) uniquely operate directly on enterprise data without data duplication, custom models, proprietary data layers, or specialized data treatments.
Demos
Click here to schedule a demo of the Pyramid Decision Intelligence Platform and to learn more about OpenAI on the platform.
Quotes
Avi Perez, CTO and Co-Founder, Pyramid Analytics : “By integrating OpenAI throughout the Pyramid Decision Intelligence Platform, we are extending our existing AI and augmented capabilities with the latest generative AI tech, transforming—and simplifying—the decision-making experience further. As a no-code/low-code platform, Pyramid is designed to extend advanced analytics—from descriptive to predictive to prescriptive—for non-technical businesspeople, allowing them to make informed decisions that drive business outcomes.”
Omri Kohl, CEO and Co-Founder, Pyramid Analytics: “At Pyramid, we believe the key to widespread adoption of data analytics requires an analytics experience that meets different people’s needs, regardless of their technical skills or analytics aptitude. By strategically integrating generative AI technologies like OpenAI, we are taking our AI vision to the next level.”
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005287/en/
Contact information
Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom